Drugs / T-Cell Infusion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01362452 | Dec 2012 → Jul 2017 | leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-Cell Infusion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01362452 ↗ |
| Modality | Cell therapy | “T-cell infusion with genetically changed T cells” NCT01362452 ↗ |
| Route | Intravenous | “The T-cell infusion is given by vein, usually over 15-30 minutes over 2 days” NCT01362452 ↗ |
| Target | CD19 | “Infusion of CD19-specific T cells derived from cord blood (CB)” NCT01362452 ↗ |